相关实验视频

Updated: Jul 25, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

开发一种INTERLEUQIN-15异构体激动剂 (N803) 用于有效免疫治疗固体恶性瘤

Grace Lui¹, Christine M Minnar¹, Patrick Soon-Shiong²

¹Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

|June 28, 2023

概括

作为一种互白素-15 (IL-15) 激动剂的N803,通过激活免疫细胞,在癌症免疫疗法中显示出有前途. 临床研究表明其安全性和有效性,特别是与其他固体瘤治疗相结合时.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

针对固体瘤的有效免疫疗法具有挑战性.
互白素-15 (IL-15) 刺激关键的免疫细胞 (NK和CD8+淋巴细胞),但具有药理动力学和安全问题.
N803是一种新型异构体IL-15激动剂,旨在克服这些局限性.

研究的目的:

审查N803.3的作用机制.
总结N803在癌症治疗中的临床前和临床研究.
突出N803在组合疗法中的潜力.

主要方法:

在瘤模型中进行临床前评估.
在癌症患者的临床试验.
审查现有的文献和研究数据.

主要成果:

在临床前模型中,N803表现出显著的Th1免疫激活和瘤抑制,由NK和CD8+T细胞介导.
在临床研究中,N803显示出了良好的安全性.
在非小细胞肺癌中,N803与nivolumab的组合产生了令人鼓舞的反应.
在BCG耐药膀癌中,N803加BCG实现了持久的完整反应.

结论:

N803是一种有前途的免疫疗法剂,具有良好的安全性.
在与其他癌症治疗,包括免疫检查点抑制剂和BCG结合使用时,N803显示出显著的潜力.
目前,N803在组合疗法中的进一步临床和临床前研究正在进行中.

关键词:

在 Anktiva® 中,您可以使用 Anktiva®在IL-15中,IL-15是最常见的.N803 没有使用过癌症免疫疗法免疫疗法细胞因子细胞因子

更多相关视频

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.